Publications by authors named "P Le Bigot"
Purpose: Surgery remains the cornerstone of localized renal cell carcinoma (RCC) care. Pembrolizumab has recently been recommended as a standard of care for RCC patients who are at high risk of recurrence. Data regarding the efficacy of ICIs either alone or in combination with ICIs or VEGF TKIs for VTT shrinkage are scarce.
View Article and Find Full Text PDFPurpose: Immune Checkpoints Inhibitors (ICI) have changed the therapeutic landscape of metastatic renal cell carcinoma first-line treatment with complete response (CR) at metastatic sites observed in 10 to 15% of cases. Delayed nephrectomy could be discussed for patients having a clinical benefit from immunotherapy-based treatment. However, it is unclear whether prior immunotherapy exposure adversely influences the complexity of surgery.
View Article and Find Full Text PDFBackground: There is a lack of published data on real-world cabozantinib use in patients with advanced renal cell carcinoma after prior vascular endothelial growth factor (VEGF)-targeted therapy.
Methods: CASSIOPE was a real-world, prospective, multicenter, non-interventional postauthorization safety study of cabozantinib in adult patients with advanced renal cell carcinoma in Europe following prior VEGF-targeted treatment (NCT03419572). Endpoints included cabozantinib utilization (dose modifications due to adverse events [AEs; primary endpoint], dose, dose modifications, and treatment duration), safety, effectiveness (progression-free survival [PFS], overall survival [OS], best overall response [BOR]), and healthcare resource utilization.
Article Synopsis
- European guidelines recommend preoperative screening and antibiotic treatment for asymptomatic bacteriuria (ABU) before urological surgeries that breach the mucosa.* -
- A study analyzed the effect of short (5 days or less) versus long (more than 5 days) antibiotic treatments on postoperative infections in 2,389 patients, finding that 4.4% experienced infections within 30 days, with no significant difference in outcomes between the treatment durations.* -
- The study concluded that there was no clear link between the duration of antibiotic treatment and urinary infections after surgery in patients with ABU, suggesting that further randomized controlled trials are needed to verify these findings.*
Article Synopsis
- Metastatic kidney cancer patients who respond well to immunotherapy are being reconsidered for primary surgery, particularly nephron-sparing surgery, due to their prolonged survival.
- A study analyzed 13 patients who had partial nephrectomy after achieving complete responses to immunotherapy, finding no positive surgical margins and acceptable complication rates.
- Results showed promising renal function and oncological outcomes, indicating that partial nephrectomy is feasible after immunotherapy, but more research is necessary for definitive conclusions.